China Pharma (CPHI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Is CASI or CPHI more profitable?

China Pharma has a net margin of -85.56% compared to CASI Pharmaceuticals' net margin of -143.18%. China Pharma's return on equity of -63.93% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
China Pharma	-85.56%	-63.93%	-31.42%

Does the media favor CASI or CPHI?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for China Pharma. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
China Pharma	Neutral

Which has higher valuation & earnings, CASI or CPHI?

China Pharma has lower revenue, but higher earnings than CASI Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.84	-$26.94M	-$2.57	-0.76
China Pharma	$4.53M	1.38	-$3.08M	N/A	N/A

Which has more volatility & risk, CASI or CPHI?

CASI Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of CASI or CPHI?

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 17.3% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend CASI or CPHI?

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 105.13%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community prefer CASI or CPHI?

CASI Pharmaceuticals received 201 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 48.91% of users gave CASI Pharmaceuticals an outperform vote while only 0.00% of users gave China Pharma an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 201 48.91%	Underperform Votes 210 51.09%
China Pharma	Outperform Votes No Votes	Underperform Votes 92 100.00%

Summary

CASI Pharmaceuticals beats China Pharma on 9 of the 15 factors compared between the two stocks.